Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals for about $6.5 billion in cash to expand into the area of autoimmune disease treatments. For access to live and exclusive video from CNBC subscribe to CNBC PRO: [ Ссылка ]
Johnson & Johnson on Wednesday agreed to pay about $6.5 billion in cash to buy Momenta Pharmaceuticals in a deal aimed at expanding its portfolio of autoimmune disease treatments.
The deal gives J&J’s Janssen unit access to Momenta’s experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases where the immune system attacks the body.
J&J hopes to get the drug approved to treat several conditions and eventually bring in blockbuster sales, as the company bulks up its pharmaceuticals unit, its largest business.
» Subscribe to CNBC TV: [ Ссылка ]
» Subscribe to CNBC: [ Ссылка ]
» Subscribe to CNBC Classic: [ Ссылка ]
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: [ Ссылка ]
Follow CNBC on LinkedIn: [ Ссылка ]
Follow CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
For info on the best credit cards go to CNBC Select:
[ Ссылка ]
#CNBC
#CNBCTV
![](https://i.ytimg.com/vi/27emcVgT3e0/mqdefault.jpg)